Alphabet’s supersecretive Calico Labs is losing its top artificial intelligence researcher as Chief Computing Officer Daphne Koller moves on to greener pastures.
“I have decided to leave Calico to pursue other professional opportunities,” Koller said in an emailed statement to Bloomberg. “I very much enjoyed my time at Calico, and have the greatest respect for the Calico team and their important and aspirational mission.”
Koller signed on with Calico in August 2016 to lead its machine learning and computational biology team. Her job? To build a team that can analyze large volumes of health data and change the way we think about aging and disease.
She joined the company from Coursera, the education tech outfit she founded in 2012.
In addition to applying existing machine learning techniques to biological data, she also intended to develop new kinds of machine learning that can change human health, she told FierceBiotech in September that year.
And her path at Calico was uncharted—because her approach was data-driven, the specific indications Calico would tackle hinged on which data are produced and what her team learned from analyzing it.
“Daphne has been instrumental in helping to build our machine learning and computing infrastructure and has made many important contributions as we aim to bring the vast capabilities of machine learning to bear on advancing our understanding of the biological mechanisms by which we age,” Calico spokesman Neil Cohen said, according to Bloomberg.
Koller’s departure is Calico’s second high-profile exit in recent months. In November, its R&D chief, Hal Barron, jumped ship to take the chief scientific officer position at GlaxoSmithKline.
The Big Pharma hired Barron, who now heads a new GSK office in San Francisco, to shake up R&D as it has seen few approvals or exciting research updates in the last few years.
By Amirah Al Idrus
Source: Fierce Biotech
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
